Effectiveness of donor selection in a blood bank
Main Article Content
Keywords
Blood-Borne Pathogens, Blood Banks, Mandatory Testing, Blood Transfusion
Abstract
Abstract
Transfusion safety in Mexico depends on 2 essential pillars: The proper clinical selection of donors and the effective application of screening tests established in current regulations. Among these tests, it is included mandatory detection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), as well as Trypanosoma cruzi and Treponema pallidum, all considered highly relevant pathogens due to their potential for bloodborne transmission and their clinical impact. Each year, thousands of people in the country acquire HCV, HBV, or HIV infections, and a significant proportion develop chronic complications that can lead to death. Given that current regulations have not been updated since 2012 and the proposed 2024 revision has not yet been approved, it is crucial to know which viruses might be present in apparently healthy donors despite the screening tests already performed on them. In this context, in this opinion article the effectiveness of donor selection and screening strategies was analyzed using the findings of an international collaborative study that analyzed pooled samples through massive parallel sequencing. Encouragingly, no traces of HIV, HBV, or HCV were detected, which suggests a favorable outlook for transfusion safety and supports the effectiveness of the procedures implemented at the National Medical Center’s Blood Bank.
References
1. Centro Nacional de la Transfusión Sanguínea. Guía Nacional de Criterios para la Selección de Donantes de Sangre y sus Componentes Sanguíneos para el Uso Terapéutico. México: CNTS; 2024.
2. Norma Oficial Mexicana NOM-253-SSA1-2012, Para la disposición de sangre humana y sus componentes con fines terapéuticos. México: Diario Oficial de la Federación; 26 de octubre de 2012.
3. Instituto Nacional de Estadística y Geografía. Estadísticas de Defunciones Registradas (EDR). México: INEGI; 2025.
4. Das K, Raturi M, Agrawal N, et al. Indian blood donor selection guidelines: Review in the context of the ongoing COVID-19 pandemic. Transfus Clin Biol. 2021;28(2):213-6.
5. Simbrón-Juárez F, Cruz-Cruz AO, Galván-Bobadilla AI, et al. Donantes de sangre, factores de riesgo y orientación sexual. Rev Med Inst Mex Seguro Soc. 2022;60(3):345-9.
6. American Red Cross. Infectious Disease, HLA and ABO Donor Qualification Testing. Infectious Disease Testing. 2019.
7. Notari E, Haynes J, Nelson D, et al. Prevalence, Incidence and Residual Risk of VIH, HBV, and HCV in the US Blood Supply 2015 to 2021, on Behalf of the US TTIMS Program. Presentation at 33rd Regional ISBT Congress; 2023 Jun 20. ISBT; 2023. Disponible en: https://www.isbtweb.org/resource/prevalence-incidence-and-residual-risk-of-hiv-hbv-and-hcv-in-the-us-blood-supply-2015to2021.html
8. Sosa Jurado F, Palencia Lara R, Xicoténcatl Grijalva C, et al. Detección de VIH, VHC y VHB en sangre donada mediante ID-NAT y el riesgo residual de transmisión iatrogénica en un banco de sangre de un hospital de tercer nivel en Puebla, México. Viruses. 2023;15(6).
9. Health Care Providers. Clinical Testing Guidance for HIV. CDC; February 10 2025.
10. Guerrero-García JJ, Zúñiga-Magaña AG, Barrera-De León JC, et al. Retrospective Study of the Seroprevalence of HIV, HCV, and HBV in Blood Donors at a Blood Bank of Western Mexico. Pathogens. 2021;10(878).
11. Lelie N. Residual risk of transfusion-transmitted hepatitis B infection by NAT-screened blood components. Transfusion (Paris). 2021;61(11):3190-201.
12. World Health Organization. Blood safety and availability. Geneva: WHO; May 30 2025.
13. Venkatakrishna S. Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus. Asian J Transfus Sci. 2014;8(1).
14. Narayan S, Baker P, Bentley A. Annual SHOT Report 2024. Manchester: Serious Hazards of Transfusion (SHOT) Steering Group; 2025. doi: 10.57911/gwcz-4q04
15. Rekha H, Neelam M. Nucleic acid testing-benefits and constraints. Asian J Transfus Sci. 2014;8(1):2-3.
16. Calderón-Carmona P, Benitez-Arvizu G, Galván-Bobadilla A. Donador con infección del VHB detectado por NAT en probable resolución clínica. Rev Med Inst Mex Seguro Soc. 2024;62 Supl 1:e5640. doi: 10.5281/zenodo.10790554
17. Rongsong D, Wenbo G, Zhongping L, et al. Comprehensive evaluation of NAT+/HBsAg– blood donors: confirmation strategies, serial testing outcomes, and S gene mutations associated with occult HBV infection. BMC Infect Dis. 2025;25:1349.
18. Bhuyan G, Zaman AU, Sultana R. Frequency of Hepatitis B, C and HIV Infections among Transfusion-Dependent Beta Thalassemia Patients in Dhaka. Infects Dis Rep. 2021;13(1):89-95.
19. Pérez Hernández JL, Murcia Sandoval MV, Bonilla Ramos A, et al. Seroprevalencia del virus de la hepatitis C en donantes del Banco de Sangre del Hospital General de México “Dr. Eduardo Liceaga”. Una evaluación de cuatro años. Ann Hepatol. 2021;24(1).
20. Santos-López G, Panduro A, Sosa-Jurado F, et al. Advances in the Elimination of Viral Hepatitis in Mexico: A Local Perspective on the Global Initiative. Pathogens. 2024;13(10). doi: 10.3390/pathogens13100859
21. Kapoor V, Briese T, Ranjan A, et al. Validation of the VirCapSeq-VERT system for differential diagnosis, detection, and surveillance of viral infections. J Clin Microbiol. 2023;62.
22. Rodríguez-Rivera J, Benitez-Arvizu G, Campos-Aguirre E. Prevalencia de periodo de ventana detectado por NAT en donadores de sangre. Revista Mexicana de Patología Clínica y Medicina de Laboratorio. 2025:89. Disponible en: https://www.fempac.org.mx/documentos/vol72_3_mt16.pdf
23. Roche. Enfermedades infecciosas: el impacto de la hepatitis y el riesgo de su evolución a cáncer de hígado. Ciudad de México: Roche; 25 de julio de 2023. Disponible en: https://www.roche.com.mx/sala-de-prensa/2024/enfermedades-infecciosas-el-impacto-de-la-hepatitis-y-el-riesgo-de-su-evolucion-a-cancer-de-higado
24. World Health Organization. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Geneva: WHO; 2024.
25. Mejía-Aguirre B, Luna-Vargas AK, Benítez-Arvizu G. Seroprevalencia de agentes infecciosos en donadores de sangre y sus componentes. Rev Med Inst Mex Seguro Soc. 2025;63(2):e6588. doi: 10.5281/zenodo.14616969
26. Cristancho JT. México enfrenta un repunte histórico de VIH: más de 12 mil casos en nueve meses encienden las alarmas sanitarias. Consultor Salud. 15 de septiembre de 2025. Disponible en: https://consultorsalud.com.mx/vih-mexico-repunte-historico-2025-salud/
27. Mejía-Domínguez AM, Soster-Contreras MA, Campos-Morales N, et al. Prevalence of HIV, Syphilis, and Hepatitis B and C Among Blood Donors in a Tertiary Care Hospital in Mexico. Venereology. 2024;3:172-182.
28. World Health Organization. HIV data and statistics. Geneva; WHO; 2025. Disponible en: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.